These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

705 related items for PubMed ID: 17355742

  • 41. Cost-effectiveness analysis of exenatide once-weekly versus dulaglutide, liraglutide, and lixisenatide for the treatment of type 2 diabetes mellitus: an analysis from the UK NHS perspective.
    Chuang LH, Verheggen BG, Charokopou M, Gibson D, Grandy S, Kartman B.
    J Med Econ; 2016 Dec; 19(12):1127-1134. PubMed ID: 27310712
    [Abstract] [Full Text] [Related]

  • 42. Health economic evaluation of insulin glargine vs NPH insulin in intensified conventional therapy for type 1 diabetes in Germany.
    Pfohl M, Schädlich PK, Dippel FW, Koltermann KC.
    J Med Econ; 2012 Dec; 15 Suppl 2():14-27. PubMed ID: 22812690
    [Abstract] [Full Text] [Related]

  • 43. Willingness to pay for diabetes drug therapy in type 2 diabetes patients: based on LEAD clinical programme results.
    Jendle J, Torffvit O, Ridderstråle M, Ericsson Å, Nilsen B, Bøgelund M.
    J Med Econ; 2012 Dec; 15 Suppl 2():1-5. PubMed ID: 22853443
    [Abstract] [Full Text] [Related]

  • 44. Cost-effectiveness of insulin detemir compared with neutral protamine Hagedorn insulin in patients with type 1 diabetes using a basal-bolus regimen in five European countries.
    Gschwend MH, Aagren M, Valentine WJ.
    J Med Econ; 2009 Jun; 12(2):114-23. PubMed ID: 19545216
    [Abstract] [Full Text] [Related]

  • 45. Patient characteristics, drug adherence patterns, and hypoglycemia costs for patients with type 2 diabetes mellitus newly initiated on exenatide or insulin glargine.
    Fabunmi R, Nielsen LL, Quimbo R, Schroeder B, Misurski D, Wintle M, Wade R.
    Curr Med Res Opin; 2009 Mar; 25(3):777-86. PubMed ID: 19203299
    [Abstract] [Full Text] [Related]

  • 46. Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands.
    Hunt B, Malkin SJP, Moes RGJ, Huisman EL, Vandebrouck T, Wolffenbuttel BHR.
    BMJ Open Diabetes Res Care; 2019 Mar; 7(1):e000705. PubMed ID: 31641522
    [Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50. A long-term analysis evaluating the cost-effectiveness of biphasic insulin lispro mix 75/25 and mix 50/50 versus long-acting basal insulin analogs in the United States.
    Pollock RF, Curtis BH, Valentine WJ.
    J Med Econ; 2012 Mar; 15(4):766-75. PubMed ID: 22413830
    [Abstract] [Full Text] [Related]

  • 51. Combination therapy with insulin glargine and exenatide: real-world outcomes in patients with type 2 diabetes.
    Levin P, Wei W, Wang L, Pan C, Douglas D, Baser O.
    Curr Med Res Opin; 2012 Mar; 28(3):439-46. PubMed ID: 22216894
    [Abstract] [Full Text] [Related]

  • 52. Switching from sitagliptin to liraglutide to manage patients with type 2 diabetes in the UK: A long-term cost-effectiveness analysis.
    Barnett AH, Arnoldini S, Hunt B, Subramanian G, Hoxer CS.
    Diabetes Obes Metab; 2018 Aug; 20(8):1921-1927. PubMed ID: 29652101
    [Abstract] [Full Text] [Related]

  • 53. Cost-utility analysis of liraglutide versus glimepiride as add-on to metformin in type 2 diabetes patients in China.
    Gao L, Zhao FL, Li SC.
    Int J Technol Assess Health Care; 2012 Oct; 28(4):436-44. PubMed ID: 23006540
    [Abstract] [Full Text] [Related]

  • 54. Cost-effectiveness of basal insulin from a US health system perspective: comparative analyses of detemir, glargine, and NPH.
    Valentine WJ, Palmer AJ, Erny-Albrecht KM, Ray JA, Cobden D, Foos V, Lurati FM, Roze S.
    Adv Ther; 2006 Oct; 23(2):191-207. PubMed ID: 16751153
    [Abstract] [Full Text] [Related]

  • 55. Healthcare resource utilization and related financial costs associated with glucose lowering with either exenatide or basal insulin: A retrospective cohort study.
    Holden SE, Morgan CL, Qiao Q, Jenkins-Jones S, Berni ER, Currie CJ.
    Diabetes Obes Metab; 2017 Aug; 19(8):1097-1105. PubMed ID: 28218819
    [Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. A short-term cost-utility analysis of insulin degludec versus insulin glargine U100 in patients with type 1 or type 2 diabetes in Denmark.
    Pollock RF, Tikkanen CK.
    J Med Econ; 2017 Mar; 20(3):213-220. PubMed ID: 27705031
    [Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 36.